← Back to Screener
Jade Biosciences, Inc. Common Stock (JBIO)
Price$17.59
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)32.51%
Price vs S&P 500 (4W)-34.68%
VGM Score71.79
Market Capitalization$876.14M
Indicated Dividend Yield (Annual)0.00%
All Metrics
Book Value / Share (Quarterly)$6.01
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.36
Price vs S&P 500 (YTD)3.65%
EPS (TTM)$-3.06
10-Day Avg Trading Volume0.86M
EPS Excl Extra (TTM)$-3.06
EPS (Annual)$-4.06
ROI (Annual)-38.32%
Cash / Share (Quarterly)$6.31
ROA (Last FY)-36.43%
EBITD / Share (TTM)$-2.97
ROE (5Y Avg)-50.48%
Cash Flow / Share (Annual)$-1.92
P/B Ratio2.96x
P/B Ratio (Quarterly)2.34x
Net Income / Employee (Annual)$-2,316,500
Net Interest Coverage (TTM)-8.23x
ROA (TTM)-47.32%
EPS Incl Extra (Annual)$-4.06
Current Ratio (Annual)21.09x
Quick Ratio (Quarterly)13.96x
3-Month Avg Trading Volume0.52M
52-Week Price Return146.53%
Revenue / Employee (TTM)$0
52-Week High$28.00
EPS Excl Extra (Annual)$-4.06
26-Week Price Return46.09%
Quick Ratio (Annual)20.33x
13-Week Price Return25.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.29x
Enterprise Value$821.05M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.82
3-Month Return Std Dev79.53%
Net Income / Employee (TTM)$-2,356,500
ROE (Last FY)-38.32%
EPS Basic Excl Extra (Annual)$-4.06
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.06
ROI (TTM)-51.34%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)118.38%
Year-to-Date Return15.04%
5-Day Price Return-17.44%
EPS Normalized (Annual)$-4.06
ROA (5Y Avg)-46.71%
Month-to-Date Return-15.64%
EBITD / Share (Annual)$-3.62
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.48%
EPS Basic Excl Extra (TTM)$-3.06
P/B Ratio (Annual)2.13x
Book Value / Share (Annual)$6.74
Price vs S&P 500 (13W)15.04%
Beta1.48x
Revenue / Share (TTM)$0.00
ROE (TTM)-51.34%
52-Week Low$6.57
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.57est. -0.49
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.43
4.43
4.44
4.44
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JBIOJade Biosciences, Inc. Common Stock | — | — | B | $17.59 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Jade Biosciences develops immunotherapies targeting autoimmune diseases using antibody-based approaches. The company's lead candidate, JADE-001, targets the APRIL pathway for IgA nephropathy treatment and is advancing toward clinical-stage development. Jade maintains two additional antibody programs in preclinical development and was founded using technology licensed from Paragon Therapeutics.